FDA.reportPublic FDA data

AMMONIA

Substance profile for UNII 5138Q19F1X, enriched with FDA NDC listings, DailyMed labels, legacy aliases, and open chemistry identifiers.

Chemical structure for AMMONIA
Structure render from NCI/CADD chemical resolver

Substance Identity#

UNII
5138Q19F1X
Preferred term
AMMONIA
Registry number
7664-41-7
EC number
231-635-3
Ingredient type
INGREDIENT SUBSTANCE
Molecular formula
H3N
Chemical structure for AMMONIA
Structure render from NCI/CADD chemical resolver

Chemical And Database Identifiers#

InChIKey
QGZKDVFQNNGYKY-UHFFFAOYSA-N
SMILES
N
RxCUI
1299884
PubChem
0
NCIt
C76698
INN ID
0

Open Chemistry Sources#

Source, Identifier, Link table
SourceIdentifierLink
PubChem InChIKey SearchQGZKDVFQNNGYKY-UHFFFAOYSA-Nhttps://pubchem.ncbi.nlm.nih.gov/#query=QGZKDVFQNNGYKY-UHFFFAOYSA-N
RxNorm1299884https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1299884
NCI ThesaurusC76698https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C76698
FDA Substance Registration System5138Q19F1Xhttps://precision.fda.gov/uniisearch/srs/unii/5138Q19F1X
European Community number231-635-3https://commonchemistry.cas.org/results?q=231-635-3

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
AMMONIAINACTIVE INGREDIENT5138Q19F1XLANSOPRAZOLE7
AMMONIAINACTIVE INGREDIENT5138Q19F1X075dbfb1-47c2-4578-a212-f8e656f0e9f92
AMMONIAINACTIVE INGREDIENT5138Q19F1XPANTOPRAZOLE SODIUM2
AMMONIAINACTIVE INGREDIENT5138Q19F1X104fea5c-cb2a-16c3-e054-00144ff88e882
ammoniaINACTIVE INGREDIENT5138Q19F1XTEMAZEPAM1
AMMONIAINACTIVE INGREDIENT5138Q19F1XIndomethacin Extended Release Capsules, USP Rx only2
AmmoniaINACTIVE INGREDIENT5138Q19F1XESOMEPRAZOLE MAGNESIUM1
AMMONIAACTIVE MOIETY5138Q19F1Xfc36eaa5-499d-4a96-a144-cffae64878a41
AMMONIAACTIVE INGREDIENT5138Q19F1Xfc36eaa5-499d-4a96-a144-cffae64878a41
AMMONIAINACTIVE INGREDIENT5138Q19F1XGABAPENTIN2
AMMONIAINACTIVE INGREDIENT5138Q19F1XVOLTAREN2
AMMONIAINACTIVE INGREDIENT5138Q19F1XIndomethacin Capsules USP, 25 mg and 50 mg5
AMMONIAINACTIVE INGREDIENT5138Q19F1XINDOMETHACIN1
AMMONIAINACTIVE INGREDIENT5138Q19F1XIndomethacin Extended – Release Capsules, USP 75 mg5
AMMONIAINACTIVE INGREDIENT5138Q19F1XDrug Facts1
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use omeprazole delayed-release capsules safely and effectively. See full prescribing information for omeprazole delayed-release capsules. OMEPRAZOLE Delayed-Release Capsules USP Initial U.S. Approval: 19895
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use OMEPRAZOLE delayed-release capsules, USP safely and effectively. See full prescribing information for OMEPRAZOLE delayed-release capsules, USP. OMEPRAZOLE Delayed-Release Capsules, USP, for oral use INITIAL U.S. APPROVAL: 19894
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use OMEPRAZOLE delayed-release capsules, USP safely and effectively. See full prescribing information for OMEPRAZOLE delayed-release capsules, USP. OMEPRAZOLE Delayed-Release Capsules, USP, for oral use INITIAL U.S. APPROVAL: 19892
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use fluoxetine capsules safely and effectively. See full prescribing information for fluoxetine capsules. FLUOXETINE capsules, USP for oral use Initial U.S. Approval: 19873
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets USP safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets USP. PANTOPRAZOLE Sodium delayed-release tablets USP for oral use Initial U.S. approval: 20001
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use OMEPRAZOLE delayed-release capsules, USP safely and effectively. See full prescribing information for OMEPRAZOLE delayed-release capsules, USP . OMEPRAZOLE Delayed-Release Capsules, USP , for oral use INITIAL U.S. APPROVAL: 198915
AMMONIAINACTIVE INGREDIENT5138Q19F1XDrug Facts3
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use fluoxetine capsules, USP safely and effectively. See full prescribing information for fluoxetine capsules, USP. FLUOXETINE Capsules, USP for Oral Use Initial U.S. Approval: 19874
AMMONIAINACTIVE INGREDIENT5138Q19F1Xf1f051d8-b8d8-4afd-84d8-82a59d9fa4fb1
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use Omeprazole delayed-release capsules safely and effectively. See full prescribing information for Omeprazole delayed-release capsules. OMEPRAZOLE delayed-release capsules, USP, for oral use Initial U.S. Approval: 198923
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use Duloxetine Delayed-release Capsules safely and effectively. See full prescribing information for Duloxetine Delayed-release Capsules. DULOXETINE delayed-release capsules USP for oral use. Initial U.S. Approval: 20042
AMMONIAINACTIVE INGREDIENT5138Q19F1XAfeditab CR (Nifedipine Extended Release Tablets)4
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use fluoxetine capsules, USP safely and effectively. See full prescribing information for fluoxetine capsules, USP. FLUOXETINE Capsules, USP for Oral Use Initial U.S. Approval: 198715
AMMONIAINACTIVE INGREDIENT5138Q19F1XERY-TAB (ERYTHROMYCIN DELAYED-RELEASE TABLETS, USP) ENTERIC-COATED ®2
AMMONIAINACTIVE INGREDIENT5138Q19F1XERY-TAB (ERYTHROMYCIN DELAYED-RELEASE TABLETS, USP) ENTERIC-COATED ®2
AMMONIAACTIVE MOIETY5138Q19F1XAller-Detox: Indoor Pollution Control1
AMMONIAACTIVE INGREDIENT5138Q19F1XAller-Detox: Indoor Pollution Control1
AMMONIAINACTIVE INGREDIENT5138Q19F1XRevised: January 2014 Glipizide Extended-Release Tablets For Oral Use Rx only2
AMMONIAINACTIVE INGREDIENT5138Q19F1XCLARAVIS™ (isotretinoin capsules USP)4
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use Omeprazole safely and effectively. See full prescribing information for Omeprazole. Omeprazole (Omeprazole) CAPSULE for ORAL use. Initial U.S. Approval: 20133
AMMONIAINACTIVE INGREDIENT5138Q19F1XGabapentin Capsules, USP 100 mg, 300 mg and 400 mg2
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use PANTOPRAZOLE SODIUM safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM. PANTOPRAZOLE SODIUM (PANTOPRAZOLE SODIUM) TABLET for ORAL use. Initial U.S. Approval: 20073
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use dicyclomine hydrochloride capsules, USP and dicyclomine hydrochloride tablets, USP safely and effectively. See full prescribing information for dicyclomine hydrochloride capsules, USP and dicyclomine hydrochloride tablets, USP. Dicyclomine hydrochloride capsules USP, for oral use Dicyclomine hydrochloride tablets USP, for oral use Initial U.S. Approval: 19501
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use ziprasidone hydrochloride capsules safely and effectively. See full prescribing information for ziprasidone hydrochloride capsules. Ziprasidone Hydrochloride Capsules Initial U.S. Approval: 20014
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use fluoxetine capsules USP safely and effectively. See full prescribing information for fluoxetine capsules USP. FLUOXETINE capsules USP for oral use Initial U.S. Approval: 19871
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use ziprasidone safely and effectively. See full prescribing information for ziprasidone. Ziprasidone Hydrochloride Capsules for Oral use Initial U.S. Approval: 20013
AMMONIAINACTIVE INGREDIENT5138Q19F1XMEXILETINE HYDROCHLORIDE CAPSULES USP 8739 8740 8741 Rx only2
AMMONIAINACTIVE INGREDIENT5138Q19F1XDRUG FACTS8
AMMONIAACTIVE MOIETY5138Q19F1XDrug Facts6
AMMONIAACTIVE INGREDIENT5138Q19F1XDrug Facts6
AMMONIAACTIVE MOIETY5138Q19F1XDrug Facts3
AMMONIAACTIVE INGREDIENT5138Q19F1XDrug Facts3
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use fluvastatin capsules safely and effectively. See full prescribing information for fluvastatin capsules. Fluvastatin Capsules, USP for oral use Initial U.S. Approval: 19932
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use fluvastatin capsules safely and effectively. See full prescribing information for fluvastatin capsules. Fluvastatin Capsules, USP for oral use Initial U.S. Approval: 19932
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use dicyclomine hydrochloride capsules, USP and dicyclomine hydrochloride tablets, USP safely and effectively. See full prescribing information for dicyclomine hydrochloride capsules, USP and dicyclomine hydrochloride tablets, USP. Dicyclomine hydrochloride capsules USP, for oral use Dicyclomine hydrochloride tablets USP, for oral use Initial U.S. Approval: 19502
AMMONIAINACTIVE INGREDIENT5138Q19F1XMyorisan TM (isotretinoin capsules, USP) 10 mg, 20 mg, 40 mg2
AMMONIAINACTIVE INGREDIENT5138Q19F1XGlipizide Extended-Release Tablets Rx only4
AMMONIAINACTIVE INGREDIENT5138Q19F1XTETRACYCLINE HYDROCHLORIDE CAPSULES USP2
AMMONIAINACTIVE INGREDIENT5138Q19F1XDrug Facts1
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use verapamil hydrochloride extended-release capsules (PM) safely and effectively. See full prescribing information for verapamil hydrochloride extended-release capsules (PM). Verapamil Hydrochloride Extended-release Capsules (PM) (Controlled Onset) for Oral use Initial U.S. Approval: 19982
AMMONIAINACTIVE INGREDIENT5138Q19F1Xb3180408-a3c0-4e02-8535-dea390a522777
AMMONIAINACTIVE INGREDIENT5138Q19F1XEtodolac Capsules and Tablets, USP2
AMMONIAINACTIVE INGREDIENT5138Q19F1XTussiCaps ® (Hydrocodone Polistirex and Chlorpheniramine Polistirex) Extended-Release Capsules CIII Rx only1
AMMONIAINACTIVE INGREDIENT5138Q19F1Xd4569486-e581-4671-b32c-1903abfa726e1
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use omeprazole delayed-release capsules safely and effectively. See full prescribing information for omeprazole delayed-release capsules. Omeprazole Delayed-Release Capsules, USP Initial U.S. Approval: 19893
ammoniaINACTIVE INGREDIENT5138Q19F1X2ed81194-be24-45a0-8dde-fbc6ad3d7abe4
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use fluoxetine capsules USP safely and effectively. See full prescribing information for fluoxetine capsules USP. Initial U.S. Approval: 19872
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use Fluoxetine safely and effectively. See full prescribing information for Fluoxetine. Fluoxetine capsules for oral use Initial U.S. Approval: 19871
AMMONIAINACTIVE INGREDIENT5138Q19F1XFULL PRESCRIBING INFORMATION These highlights do not include all the information needed to use OMEPRAZOLE DELAYED-RELEASE safely and effectively. See full prescribing information for OMEPRAZOLE DELAYED-RELEASE. OMEPRAZOLE DELAYED-RELEASE (omeprazole) capsule, delayed release for oral use Initial U.S. Approval: 19893
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use Voltaren® Gel safely and effectively. See full prescribing information for Voltaren® Gel. Initial U.S. Approval: 19885
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use REYATAZ safely and effectively. See full prescribing information for REYATAZ. REYATAZ ® (atazanavir sulfate) Capsules Initial U.S. Approval: 20032
AMMONIAINACTIVE INGREDIENT5138Q19F1Xe69fa3b1-f8eb-4289-bc79-f40f25cfa4181
AMMONIAINACTIVE INGREDIENT5138Q19F1XAmoxicillin Capsules, Tablets and Powder for Oral Suspension, USP6
AMMONIAINACTIVE INGREDIENT5138Q19F1XDronabinol Capsules, USP CIII Rx only3
AMMONIAINACTIVE INGREDIENT5138Q19F1XRIFAMPIN CAPSULES, USP2
AMMONIAINACTIVE INGREDIENT5138Q19F1XIndomethacin Capsules USP, 25 mg and 50 mg3
AMMONIAINACTIVE INGREDIENT5138Q19F1XLithium Carbonate Capsules USP Rx Only6
AMMONIAINACTIVE INGREDIENT5138Q19F1XNeomycin and Polymyxin B Sulfates and Gramicidin Ophthalmic Solution USP (Sterile)3
AMMONIAINACTIVE INGREDIENT5138Q19F1XRX Only1
AMMONIAINACTIVE INGREDIENT5138Q19F1XGFS BIOPROTECT ALOE VERA HAND SANITIZER-ALCOHOL FREE-GEL8
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use tamsulosin hydrochloride capsules safely and effectively. See full prescribing information for tamsulosin hydrochloride capsules. Tamsulosin Hydrochloride Capsules, 0.4 mg Initial U.S. Approval: 19973
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use fluoxetine capsules USP safely and effectively. See full prescribing information for fluoxetine capsules USP. Initial U.S. Approval: 19879
AMMONIAINACTIVE INGREDIENT5138Q19F1XRIFAMPIN CAPSULES, USP2
AMMONIAINACTIVE INGREDIENT5138Q19F1XStrazepam17
AMMONIAINACTIVE INGREDIENT5138Q19F1XFluoxetine 10 mg These highlights do not include all the information needed to use fluoxetine capsules USP safely and effectively. See full prescribing information for fluoxetine capsules USP. Initial U.S. Approval: 19879
AMMONIAINACTIVE INGREDIENT5138Q19F1XFluoxetine 10 mg These highlights do not include all the information needed to use fluoxetine capsules USP safely and effectively. See full prescribing information for fluoxetine capsules USP. Initial U.S. Approval: 19878
AMMONIAINACTIVE INGREDIENT5138Q19F1XThese highlights do not include all the information needed to use tamsulosin hydrochloride safely and effectively. See full prescribing information for tamsulosin hydrochloride. Tamsulosin Hydrochloride Capsules USP*, 0.4 mg Initial U.S. Approval: 19971
AMMONIAINACTIVE INGREDIENT5138Q19F1XDILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULES, USP2
AMMONIAINACTIVE INGREDIENT5138Q19F1XIndomethacin Capsules USP, 25 mg2
AMMONIAINACTIVE INGREDIENT5138Q19F1XSKIN EFFECTS BY DR. JEFFREY DOVER GLYCOLIC DAY CREAM SPF 3010
AMMONIAINACTIVE INGREDIENT5138Q19F1XGlytone Retexturize Body2
AMMONIAINACTIVE INGREDIENT5138Q19F1XLithium Carbonate Capsules USP Rx Only4
AMMONIAINACTIVE INGREDIENT5138Q19F1XLithium Carbonate Capsules USP Rx Only2
AMMONIAINACTIVE INGREDIENT5138Q19F1XERY-TAB® (erythromycin delayed-release tablets, USP) ENTERIC-COATED1
AMMONIAINACTIVE INGREDIENT5138Q19F1X3bb441fb-3c40-45d6-bb10-c761cc8e83b02
AMMONIAINACTIVE INGREDIENT5138Q19F1XLithium Carbonate Capsules USP 150 mg, 300 mg and 600 mg2
AMMONIAINACTIVE INGREDIENT5138Q19F1XDILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULES, USP1
AMMONIAINACTIVE INGREDIENT5138Q19F1XRifampin Capsules, USP1
AMMONIAINACTIVE INGREDIENT5138Q19F1X4b5513c3-b57f-46f1-9855-dad1063aa4c92
AMMONIAINACTIVE INGREDIENT5138Q19F1X322513fd-6be0-4cd9-a0ea-7e4b5b5783362
AMMONIAINACTIVE INGREDIENT5138Q19F1XLithium Carbonate Capsules USP 150 mg, 300 mg and 600 mg2
AMMONIAINACTIVE INGREDIENT5138Q19F1X61bf535a-3ed5-4c50-b285-6dcee0624c2d2
ammoniaINACTIVE INGREDIENT5138Q19F1XTEMAZEPAM CAPSULE [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC]3945
AMMONIAINACTIVE INGREDIENT5138Q19F1XINDOMETHACIN CAPSULE [LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALITY CARE PRODUCTS LLC]3911
ammoniaINACTIVE INGREDIENT5138Q19F1XCELLCEPT (MYCOPHENOLATE MOFETIL) TABLET, FILM COATED [LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALITY CARE PRODUCTS LLC]3807
AMMONIAINACTIVE INGREDIENT5138Q19F1XMEXILETINE HYDROCHLORIDE CAPSULE [LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALITY CARE PRODUCTS LLC]3749
AMMONIAINACTIVE INGREDIENT5138Q19F1XOMEPRAZOLE CAPSULE, DELAYED RELEASE [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC]3741
AMMONIAINACTIVE INGREDIENT5138Q19F1XETODOLAC CAPSULE [LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALTIY CARE PRODUCTS LLC]3619
AMMONIAINACTIVE INGREDIENT5138Q19F1XINDOMETHACIN CAPSULE, EXTENDED RELEASE [LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALITY CARE PRODUCTS LLC]3231
AMMONIAINACTIVE INGREDIENT5138Q19F1XVOLTAREN (DICLOFENAC SODIUM) GEL [LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALITY CARE PRODUCTS LLC]3191
AMMONIAINACTIVE INGREDIENT5138Q19F1XTRAMADOL HYDROCHLORIDE (TRAMADOL HYDROCHLORIDE) TABLET, EXTENDED RELEASE TRAMADOL HYDROCHLORIDE (TRAMADOL HYDROCHLORIDE) TABLET, EXTENDED RELEASE [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC]3040
AMMONIAINACTIVE INGREDIENT5138Q19F1XLICORICE COUGHING LIQUID (GUAIFENESIN) LIQUID [MAYINGLONG PHARMACEUTICAL GROUP CO., LTD]2997
AMMONIAINACTIVE INGREDIENT5138Q19F1XAFEDITAB CR (NIFEDIPINE) TABLET, FILM COATED, EXTENDED RELEASE [BRYANT RANCH PREPACK]1000
AMMONIAINACTIVE INGREDIENT5138Q19F1XDULOXETINE CAPSULE, DELAYED RELEASE [BRYANT RANCH PREPACK]1000
AMMONIAINACTIVE INGREDIENT5138Q19F1XDULOXETINE CAPSULE, DELAYED RELEASE [BRYANT RANCH PREPACK]1000
AMMONIAINACTIVE INGREDIENT5138Q19F1XGLIPIZIDE ER (GLIPIZIDE) TABLET, FILM COATED, EXTENDED RELEASE [BRYANT RANCH PREPACK]1000
AMMONIAINACTIVE INGREDIENT5138Q19F1XLANSOPRAZOLE CAPSULE, DELAYED RELEASE PELLETS [BRYANT RANCH PREPACK]1000
AMMONIAINACTIVE INGREDIENT5138Q19F1XVOLTAREN (DICLOFENAC SODIUM) GEL [BRYANT RANCH PREPACK]1000
AMMONIAINACTIVE INGREDIENT5138Q19F1XDIVALPROEX SODIUM (DIVALPROEX SODIUM ) TABLET, EXTENDED RELEASE [REMEDYREPACK INC. ]113
AMMONIAINACTIVE INGREDIENT5138Q19F1XDIVALPROEX SODIUM (DIVALPROEX SODIUM ) TABLET, EXTENDED RELEASE [REMEDYREPACK INC. ]107
AMMONIAINACTIVE INGREDIENT5138Q19F1XISENTRESS (RALTEGRAVIR) TABLET, FILM COATED ISENTRESS (RALTEGRAVIR) TABLET, CHEWABLE ISENTRESS (RALTEGRAVIR) GRANULE, FOR SUSPENSION [MERCK SHARP & DOHME CORP.]49
AMMONIAINACTIVE INGREDIENT5138Q19F1XVICTRELIS (BOCEPREVIR) CAPSULE [MERCK SHARP & DOHME CORP.]33
AMMONIAINACTIVE INGREDIENT5138Q19F1XOMEPRAZOLE CAPSULE, DELAYED RELEASE PELLETS [ACTAVIS PHARMA, INC.]31
ammoniaINACTIVE INGREDIENT5138Q19F1XCELLCEPT (MYCOPHENOLATE MOFETIL) TABLET, FILM COATED CELLCEPT (MYCOPHENOLATE MOFETIL) CAPSULE CELLCEPT (MYCOPHENOLATE MOFETIL HYDROCHLORIDE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION CELLCEPT (MYCOPHENOLATE MOFETIL) POWDER, FOR SUSPENSION [GENENTECH, INC.]26
AMMONIAINACTIVE INGREDIENT5138Q19F1XOMEPRAZOLE CAPSULE, DELAYED RELEASE [KREMERS URBAN PHARMACEUTICALS INC.]23